Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

The Journal of general virology - 1 Aug 2018

Teraoka Yuji, Uchida Takuro, Imamura Michio, Hiraga Nobuhiko, Osawa Mitsutaka, Kan Hiromi, Saito Yuhei, Tsuge Masataka, Abe-Chayama Hiromi, Hayes C Nelson, Makokha Grace Naswa, Aikata Hiroshi, Miki Daiki, Ochi Hidenori, Ishida Yuji, Tateno Chise, Chayama Kazuaki

Abstract excerpt

Combined daclatasvir (DCV)/asunaprevir (ASV) plus beclabuvir (BCV) treatment shows a high virological response for genotype 1b chronic hepatitis C patients. However, its efficacy for patients for whom previous direct-acting antiviral (DAA) therapy failed is not known. We analysed the efficacy of DCV/ASV/BCV treatment for HCV-infected mice and chronic hepatitis patients. Human hepatocyte chimaeric mice were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzazepines
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Isoquinolines

Share to Protease Inhibitors

Share to Pyrrolidines

Share to Treatment Failure

Share to Viremia

Source

Identifiers

PMID: 29916799
DOI: 10.1099/jgv.0.001091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.PMID 29916799Read ↗

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.Semantic proximity Read ↗

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.Semantic proximity Read ↗

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.Semantic proximity Read ↗

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.Semantic proximity Read ↗

Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.Semantic proximity Read ↗

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.Semantic proximity Read ↗

Management of direct antiviral agent failures.Semantic proximity Read ↗

Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.Semantic proximity Read ↗

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.Semantic proximity Read ↗

Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.Semantic proximity Read ↗

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.Semantic proximity Read ↗

New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.